Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.
Metrics to compare | SPRINT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRINTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.6x | −3.0x | −0.5x | |
PEG Ratio | 0.01 | −0.08 | 0.00 | |
Price / Book | 2.8x | 2.6x | 2.6x | |
Price / LTM Sales | 2.0x | 5.1x | 3.2x | |
Upside (Analyst Target) | 5.1% | 82.1% | 45.2% | |
Fair Value Upside | Unlock | 16.7% | 6.4% | Unlock |